Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An oligodendroglioma that arises from the central nervous system and occurs during childhood.
Biomarker and diagnostic research for childhood oligodendroglioma has been reported in the published literature.
37 clinical trials registered, 20 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE4, 4 PHASE3, 9 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07468136](https://clinicaltrials.gov/study/NCT07468136) |
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 7:23 PM UTC
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas |
PHASE1 |
Mayo Clinic |
RECRUITING |
[NCT04648462](https://clinicaltrials.gov/study/NCT04648462) | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | — | Maastricht Radiation Oncology | RECRUITING |
[NCT05303519](https://clinicaltrials.gov/study/NCT05303519) | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | PHASE3 | Nuvation Bio Inc. | RECRUITING |
[NCT05331521](https://clinicaltrials.gov/study/NCT05331521) | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). | PHASE3 | University Hospital Heidelberg | RECRUITING |
[NCT05956821](https://clinicaltrials.gov/study/NCT05956821) | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | PHASE1 | University of Miami | RECRUITING |
201 publications have been identified in PubMed for childhood oligodendroglioma. Kisho has analyzed 104 by research type. Research spans Review / Meta-Analysis (30%), Basic Science / Preclinical (18%), and Diagnostic / Biomarker (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 31 | 30% |
Laboratory research | 19 | 18% |
Testing and diagnosis research | 17 | 16% |
Disease patterns and progression | 13 | 13% |
Patient case studies | 10 | 10% |
Clinical study results | 8 | 8% |
Other research | 4 | 4% |
New treatment approaches | 2 | 2% |
Prost D (2026). [PMID: 41627174](https://pubmed.ncbi.nlm.nih.gov/41627174/). *Clin Cancer Res*. [Clinical Trial Publication]
Fujimoto K (2026). [PMID: 41677944](https://pubmed.ncbi.nlm.nih.gov/41677944/). *Acta Neuropathol*. [Basic Science / Preclinical]
Virata MC (2026). [PMID: 41903203](https://pubmed.ncbi.nlm.nih.gov/41903203/). *Neuro Oncol*. [Basic Science / Preclinical]
Tork CA (2026). [PMID: 32644610](https://pubmed.ncbi.nlm.nih.gov/32644610/). *Unknown Journal*. [Clinical Trial Publication]
Brat DJ (2026). [PMID: 42152226](https://pubmed.ncbi.nlm.nih.gov/42152226/). *Neuro Oncol*. [Review / Meta-Analysis]
Darlix A (2026). [PMID: 41460180](https://pubmed.ncbi.nlm.nih.gov/41460180/). *Neuro Oncol*. [Basic Science / Preclinical]
Peters KB (2026). [PMID: 41201564](https://pubmed.ncbi.nlm.nih.gov/41201564/). *CNS Drugs*. [Review / Meta-Analysis]
Johnson KC (2026). [PMID: 42236943](https://pubmed.ncbi.nlm.nih.gov/42236943/). *Nature*. [Basic Science / Preclinical]
Martell E (2026). [PMID: 41825848](https://pubmed.ncbi.nlm.nih.gov/41825848/). *Cancer Lett*. [Review / Meta-Analysis]
Wei YY (2026). [PMID: 42252214](https://pubmed.ncbi.nlm.nih.gov/42252214/). *Zhonghua Bing Li Xue Za Zhi*. [Epidemiology / Natural History]